Steve R. Bailey
@Frazier Life Sciences Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.
Assets under management
The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ALLOAllogene Therapeutics Inc
| 0.33% | $8.03M 2.868M shares@ $2.8 avg price | |
PBYIPuma Biotechnology Inc
| 0.32% | $7.81M 3.063M shares@ $2.56 avg price | |
ADVMAdverum Biotechnologies Inc
| 0.31% | $7.506M 1.069M shares@ $7.03 avg price | |
ETNB89bio Inc
| 0.3% | $7.4M 1M shares@ $7.4 avg price | |
ACADAcadia Pharmaceuticals Inc
| 0.29% | $7.234M 470,338 shares@ $15.38 avg price | |
ARVNArvinas Inc
| 0.29% | $7.028M 285,331 shares@ $24.64 avg price | |
PEPGPepgen Inc
| 0.25% | $6.008M 702,694 shares@ $8.56 avg price | Decreased -53.24% |
ELEVElevation Oncology Inc
| 0.15% | $3.596M 5.994M shares@ $0.6 avg price | Increased 102.59% |
NAMSWNewamsterdam Pharma Company
| 0.15% | $3.502M 500,333 shares@ $7.0 avg price | |
IMCRImmunocore Hldgs Plc
| 0.14% | $3.386M 108,762 shares@ $31.13 avg price |